Redhill Biopharma successfully meets primary endpoint in Phase III study of RHB-105 for H. pylori infection

RedHill Biopharma Ltd., an Israeli biopharmaceutical company focused on late clinical-stage, proprietary, orally-administered, small molecule drugs for inflammatory and gastrointestinal diseases, including gastrointestinal cancers, today announced positive top-line results from its Phase III study with RHB-105 for the treatment of Helicobacter pylori (H. pylori) bacterial...

Read More

Lyxumia (lixisenatide) demonstrated cardiovascular safety in people with type 2 diabetes and high CV risk

Sanofi has announced the presentation of full results of the Phase IIIb ELIXA study, which was designed to assess the cardiovascular (CV) safety of Lyxumia® (lixisenatide) in adults with type 2 diabetes and high CV risk. As previously reported, lixisenatide met the pre-specified criterion of non-inferiority versus placebo for the composite primary endpoint of CV death,...

Read More

Clinical trial using dorsaVi sensors demonstrates significant reduction in back pain

New data from a cluster randomised controlled trial has demonstrated that back pain patients monitored and treated using wearable movement sensors from dorsaVi Ltd (ASX:DVL) had a significant and sustained improvement in pain and functional ability.Across all primary outcome measures, participants treated with the dorsaVi sensors with biofeedback showed a 35 % to 47 %...

Read More

Massachusetts General Hospital launches phase II trial of BCG vaccine to reverse type 1 diabetes

FDA approval of trial testing generic vaccine announced at ADA Scientific Sessions A phase II clinical trial testing the ability of the generic vaccine bacillus Calmette-Guérin (BCG) to reverse advanced type 1 diabetes has received approval from the U.S. Food and Drug Administration (FDA). The approval of this trial, which will shortly begin enrolling qualified patients,...

Read More

NightstaRx and The University of Alberta announce the start of the first Canadian gene therapy study to treat Choroideremia

NightstaRx Ltd (“Nightstar”), the biopharmaceutical company specialising in bringing therapies for retinal dystrophies to patients, announces that the University of Alberta, has begun enrolling and dosing subjects in a Phase II clinical trial of the Company’s gene therapy for the treatment of choroideremia (CHM). This gene therapy approach uses a viral vector known as...

Read More

More than 95% of the global population has at least one health problem, study finds

The largest and most in-depth study of global health trends to date finds that more than 95% of the world’s population has health problems, with more than a third of us experiencing five or more conditions. The results of the Global Burden of Disease Study 2013 (GBD 2013) were recently published inThe Lancet.Lead study author Prof. Theo Vos, of the Institute of Health...

Read More